Jonathan Tayco

Jonathan Tayco's Title

Jonathan Tayco currently serves as the Vice President of Program Management and Business Operations at Capricor. Since joining the company in 2023, he has been pivotal in overseeing strategic planning, business operations, product development, and commercialization efforts. His leadership is instrumental in driving Capricor's mission to advance innovative biotechnological solutions.

Jonathan Tayco's Company

Jonathan Tayco joined Capricor in 2023, bringing a wealth of expertise in biotechnology. Capricor is dedicated to developing transformative cell and exosome-based therapies for treating and preventing a broad spectrum of diseases. With Jonathan's extensive background in strategic and operational roles, he significantly contributes to Capricor's innovative pipeline and commercial strategies.

Jonathan Tayco's Education and Expertise

Jonathan Tayco earned his Bachelor of Science in Biochemistry/Molecular Biology from the Richard Stockton University of New Jersey. With over 20 years in the biotechnology field, Jonathan's expertise spans strategic planning, business operations, product development, and portfolio management. His educational background and extensive industry experience make him a formidable leader in biopharma and biotech sectors.

Jonathan Tayco's Background

Jonathan Tayco has a rich history in the biotechnology field, having held various leadership roles in prominent companies such as Amgen, Applied Biosystems, and Life Technologies. His tenure at Adverum and Kite focused on CMC programs throughout drug development and commercialization. Notably, he played a crucial role in the BLA approval of YESCARTA®, a groundbreaking cell therapy for large B-cell lymphoma. Jonathan has also served as the Vice President of Strategy and Business Operations at Celularity, Inc., where he was responsible for corporate strategic planning and operational excellence.

Jonathan Tayco's Achievements

Jonathan Tayco's career is marked by significant achievements, including his integral role in the BLA approval of YESCARTA®, one of the first approved cell therapy treatments for large B-cell lymphoma. As a lead consultant and adviser, he has partnered with various biopharma and biotech companies to support their clinical and operational readiness. His strategic vision and operational expertise have consistently driven successful product developments and commercializations across the industry.